公开(公告)号：EP2029747A1

公开(公告)日：2009-03-04

申请号：EP07719028.8

申请日：2007-06-04

申请人： Melbourne Health ,  Austin Health ,  Bayside Health ,  Southern Health ,  St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen ,  AYRES, Anna ,  YUEN, Lilly, Ka Wai ,  ANGUS, Peter, William ,  SASADEUSZ, Joseph, John ,  DESMOND, Paul ,  TILLMAN, Hans ,  BOCK, Thomas ,  SIEVERT, William ,  LEWIN, Sharon

IPC分类号： C12N15/51 ,  C12N7/00 ,  C12Q1/70

CPC分类号： C12Q1/706 ,  A61K39/12 ,  A61K39/29 ,  C07K14/005 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12Q2600/156

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.

公开(公告)号：EP1874923A1

公开(公告)日：2008-01-09

申请号：EP06721332.2

申请日：2006-04-04

申请人： Melbourne Health ,  St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne ,  Austin Health

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen ,  AYRES, Anna ,  LITTLEJOHN, Margaret ,  DESMOND, Paul ,  ANGUS, Peter, William

IPC分类号： C12N7/01 ,  A61K39/00 ,  C12Q1/70 ,  C12N15/01 ,  C12N15/36 ,  C12N15/51

CPC分类号： C12N15/86 ,  A61K2039/525 ,  C07K14/005 ,  C12N7/00 ,  C12N2730/10122 ,  C12Q1/706

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

公开(公告)号：EP1692278A1

公开(公告)日：2006-08-23

申请号：EP04789595.8

申请日：2004-10-20

申请人： Melbourne Health ,  Austin Health ,  Southern Health ,  Bayside Health ,  St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen, Alister ,  AYRES, Anna ,  YUEN, Lilly, Ka Wai ,  SASADEUSZ, Joseph, John

IPC分类号： C12N7/00 ,  C07K14/02 ,  C12Q1/70

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2730/10122 ,  C12Q1/706

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

公开(公告)号：EP1692278B1

公开(公告)日：2013-07-03

申请号：EP04789595.8

申请日：2004-10-20

申请人： Melbourne Health ,  Austin Health ,  Southern Health ,  Alfred Health ,  St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen, Alister ,  AYRES, Anna ,  YUEN, Lilly, Ka Wai ,  SASADEUSZ, Joseph, John ,  Angus, Peter William ,  Sievert, William ,  Lewin, Sharon Ruth ,  Desmond, Paul Vincent ,  Bell. Sally Jane

IPC分类号： C12N7/00 ,  C12Q1/70 ,  C07K14/005

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2730/10122 ,  C12Q1/706

公开(公告)号：EP1948800A1

公开(公告)日：2008-07-30

申请号：EP06790408.6

申请日：2006-10-20

申请人： Melbourne Health ,  Austin Health

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen ,  AYRES, Anna ,  LITTLEJOHN, Margaret ,  ANGUS, Peter, William

IPC分类号： C12N15/51 ,  A61K35/76 ,  C12N7/06

CPC分类号： A61K35/76 ,  C12N7/00 ,  C12N2730/10132 ,  C12Q1/18

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

公开(公告)号：EP1948800B1

公开(公告)日：2015-12-23

申请号：EP06790408.6

申请日：2006-10-20

申请人： Melbourne Health ,  Austin Health

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen ,  AYRES, Anna ,  LITTLEJOHN, Margaret ,  ANGUS, Peter, William

IPC分类号： C12N15/51 ,  A61K35/76 ,  C12N7/06

CPC分类号： A61K35/76 ,  C12N7/00 ,  C12N2730/10132 ,  C12Q1/18

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

摘要翻译： 本发明一般涉及对诸如核苷或核苷酸类似物或其他DNA聚合酶拮抗剂的药物的敏感性降低和/或与免疫试剂降低的相互作用的病毒变体。 更具体地，本发明涉及对核苷或核苷酸类似物或其他DNA聚合酶拮抗剂表现出完全或部分抗性和/或降低与病毒表面成分抗体的相互作用的乙型肝炎病毒（HBV）变体，包括对这些抗体的敏感性降低。 本发明进一步考虑了用于检测这种病毒变体的测定法，该测定法可用于监测抗病毒治疗方案和开发针对病毒剂，特别是HBV变体的新的或修饰的疫苗。 本发明还考虑使用病毒变体来筛选和/或开发或设计能够抑制病毒感染，复制和/或释放的试剂。

公开(公告)号：EP1476543B1

公开(公告)日：2014-05-14

申请号：EP03700697.0

申请日：2003-02-05

申请人： Melbourne Health ,  Austin Health ,  Southern Health

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen, Alister ,  AYRES, Anna ,  ANGUS, Peter, William ,  SIEVERT, William, c/oMonash Medical Centre

IPC分类号： C12N7/00 ,  C12N7/01 ,  C12N9/12 ,  C07K14/02 ,  A61K39/29 ,  C12Q1/70

CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N9/1276 ,  C12N2710/14143 ,  C12N2730/10122 ,  C12Q1/706

公开(公告)号：EP1499712A1

公开(公告)日：2005-01-26

申请号：EP03709442.2

申请日：2003-04-11

申请人： Melbourne Health ,  Austin Health ,  Southern Health

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen, Alister ,  AYRES, Anna ,  COLLEDGE, Danielle ,  SASADEUSZ, Joseph,Melbourne Health ,  TILLMANN, Hans ,  ANGUS, Peter, William ,  SIEVERT, William,Department of Medicine

IPC分类号： C12N7/00 ,  C12N15/01 ,  C12N15/36 ,  C12N15/51 ,  C12Q1/70

CPC分类号： C12Q1/6876 ,  C07K14/005 ,  C12N7/00 ,  C12N2730/10122

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

摘要翻译： 本发明涉及用于确定乙型肝炎病毒（HBV）的潜力的方法，所述变体表现出对阿德福韦酯，ADV和/或替诺福韦，TFV的敏感性降低。 本发明还涉及对ADV和/或TFV具有降低的敏感性的分离的HBV变体。 本发明进一步考虑了用于检测对这种病毒变体具有抑制活性的试剂的方法，以及这种病毒变体在抗HBV药物的合理设计中的用途以及用于制备用于治疗和/或预防HBV的药物 感染。

公开(公告)号：EP1169452A1

公开(公告)日：2002-01-09

申请号：EP00915035.0

申请日：2000-04-07

申请人： Melbourne Health

发明人： BARTHOLOMEUSZ, Angeline ,  LITTLEJOHN, Margaret ,  AYRES, Anna ,  LOCARNINI, Stephen

IPC分类号： C12N15/13 ,  C12N7/01 ,  C12N15/36

CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/005 ,  C07K16/082 ,  C12N2730/10122

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.

公开(公告)号：EP1297109B1

公开(公告)日：2011-11-23

申请号：EP01937883.5

申请日：2001-06-08

申请人： Melbourne Health ,  Austin And Repatriation Medical Centre ,  CENTRAL SYDNEY AREA HEALTH SERVICE

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen, Alister ,  AYRES, Anna ,  LITTLEJOHN, Margaret, Rose ,  MCCAUGHAN, Geoffrey, William ,  ANGUS, Peter, William

IPC分类号： C12N7/00 ,  C12N15/51 ,  C12N15/54 ,  A61K39/29 ,  C12Q1/68

CPC分类号： C07K14/005 ,  A61K2039/525 ,  C12N9/1252 ,  C12N2730/10122 ,  C12Q1/706 ,  C12Q2600/156

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.